Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIGTIM trial of ruxolitinib for inclusion body myositis
2023-507666-32-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib and Placebo-COD Research Private Ltd in inclusion body myositis (IBM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in 6-minute walk distance. Planned start Oct 2024; status: authorised.
02
Drugs
ruxolitinibPlacebo-COD Research Private Ltd
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2023-507666-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507666-32-00.